Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa

Infection, Genetics and Evolution

Volumn 7, Issue 5, 2007, Pages 562-569

  Holmgren, Gabrielle ^a   Hamrin, Johan ^a   Svärd, Jenny ^a   Mårtensson, Andreas ^a,b   Gil, José Pedro ^a,c   Björkman, Anders ^a  

^a Malaria Research Laboratory   (Sweden)

^b Kullbergska Hospital   (Sweden)

^c UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

ACT; Amodiaquine; Desethylamodiaquine; Kenya; Malaria; pfcrt; pfmdr1; Plasmodium falciparum; Resistance; Zanzibar

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN; ARTESUNATE; CHLOROQUINE; FANSIDAR;

AFRICA; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE MUTATION; HAPLOTYPE; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALARIA; MOLECULAR GENETICS; MONOTHERAPY; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; TANZANIA;

AMODIAQUINE; ANIMALS; ARTEMISININS; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; KENYA; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ODDS RATIO; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SELECTION (GENETICS); TANZANIA;

ARTESUNATE; PLASMODIUM FALCIPARUM;

EID: 34548356553     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2007.03.005     Document Type: Article

References (36)

1. Adjuik M., Agnamey P., Babiker A., Borrmann S., Brasseur P., Cisse M., Cobelens F., Diallo S., Faucher J.F., Garner P., Gikunda S., Kremsner P.G., Krishna S., Lell B., Loolpapit M., Matsiegui P.B., Missinou M.A., Mwanza J., Ntoumi F., Olliaro P., Osimbo P., Rezbach P., Some E., and Taylor W.R. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359 9315 (2002) 1365-1372
2. Alifrangis M., Dalgaard M.B., Lusingu J.P., Vestergaard L.S., Staalsoe T., Jensen A.T., Enevold A., Ronn A.M., Khalil I.F., Warhurst D.C., Lemnge M.M., Theander T.G., and Bygbjerg I.C. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J. Infect. Dis. 193 12 (2006) 1738-1741
3. Ariey F., Fandeur T., Durand R., Randrianarivelojosia M., Jambou R., Legrand E., Ekala M.T., Bouchier C., Cojean S., Duchemin J.B., Robert V., Le Bras J., and Mercereau-Puijalon O. Invasion of Africa by a single pfcrt allele of South East Asian type. Malar. J. 5 (2006) 34
4. Ashley E.A., and White N.J. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18 6 (2005) 531-536
5. Bjorkman A., and Bhattarai A. Public health impact of drug resistant Plasmodium falciparum malaria. Acta Trop. 94 3 (2005) 163-169
6. Bjorkman J., Nagaev I., Berg O.G., Hughes D., and Andersson D.I. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287 5457 (2000) 1479-1482
7. Cox-Singh J., Singh B., Alias A., and Abdullah M.S. Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Trans. R. Soc. Trop. Med. Hyg. 89 4 (1995) 436-437
8. Djimde A., Doumbo O.K., Cortese J.F., Kayentao K., Doumbo S., Diourte Y., Dicko A., Su X.Z., Nomura T., Fidock D.A., Wellems T.E., Plowe C.V., and Coulibaly D. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344 4 (2001) 257-263
9. Dokomajilar C., Lankoande Z.M., Dorsey G., Zongo I., Ouedraogo J.B., and Rosenthal P.J. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am. J. Trop. Med. Hyg. 75 1 (2006) 162-165
10. Duraisingh M.T., and Cowman A.F. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 94 3 (2005) 181-190
11. Duraisingh M.T., Roper C., Walliker D., and Warhurst D.C. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol. Microbiol. 36 4 (2000) 955-961
12. Fidock D.A., Nomura T., Talley A.K., Cooper R.A., Dzekunov S.M., Ferdig M.T., Ursos L.M., Sidhu A.B., Naude B., Deitsch K.W., Su X.Z., Wootton J.C., Roepe P.D., and Wellems T.E. Mutations in the P. falciparum digestive vacuole transmembrane protein pfcrt and evidence for their role in chloroquine resistance. Mol. Cell 6 4 (2000) 861-871
13. Gupta S., Thapar M.M., Mariga S.T., Wernsdorfer W.H., and Bjorkman A. Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp. Parasitol. 100 1 (2002) 28-35
14. Happi C.T., Gbotosho G.O., Folarin O.A., Bolaji O.M., Sowunmi A., Kyle D.E., Milhous W., Wirth D.F., and Oduola A.M. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am. J. Trop. Med. Hyg. 75 1 (2006) 155-161
15. Hastings I.M. Complex dynamics and stability of resistance to antimalarial drugs. Parasitology 132 5 (2006) 615-624
16. Hayward R., Saliba K.J., and Kirk K. Pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol. Microbiol. 55 4 (2005) 1285-1295
17. Holmgren G., Gil J.P., Ferreira P.M., Veiga M.I., Obonyo C.O., and Bjorkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect. Genet. Evol. 6 4 (2006) 309-314
18. Humphreys G.S., Merinopoulos I., Ahmed J., Whitty C.J., Mutabingwa T.K., Sutherland C.J., and Hallett R.L. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 51 3 (2007) 991-997
19. Krishna S., Woodrow C.J., Staines H.M., Haynes R.K., and Mercereau-Puijalon O. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol. Med. 12 5 (2006) 200-205
20. Mariga S.T., Gil J.P., Wernsdorfer W.H., and Bjorkman A. Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in Plasmodium falciparum in vitro. Acta Trop. 93 3 (2005) 221-231
21. Martensson A., Stromberg J., Sisowath C., Msellem M.I., Gil J.P., Montgomery S.M., Olliaro P., Ali A.S., and Bjorkman A. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 41 8 (2005) 1079-1086
22. Menard D., Yapou F., Manirakiza A., Djalle D., Matsika-Claquin M.D., and Talarmin A. Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am. J. Trop. Med. Hyg. 75 3 (2006) 381-387
23. Mita T., Kaneko A., Hombhanje F., Hwaihwanje I., Takahashi N., Osawa H., Tsukahara T., Masta A., Lum J.K., Kobayakawa T., Ishizaki T., and Bjorkman A. Role of pfmdr1 mutations on chloroquine resistance in Plasmodium falciparum isolates with pfcrt K76T from Papua New Guinea. Acta Trop. 98 2 (2006) 137-144
24. Mutabingwa T.K., Anthony D., Heller A., Hallett R., Ahmed J., Drakeley C., Greenwood B.M., and Whitty C.J. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 9469 (2005) 1474-1480
25. Ochong E.O., van den Broek I.V., Keus K., and Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am. J. Trop. Med. Hyg. 69 2 (2003) 184-187
26. Olliaro P., and Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst. Rev. 2 (2003) CD000016
27. Price R.N., Cassar C., Brockman A., Duraisingh M., van Vugt M., White N.J., Nosten F., and Krishna S. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43 12 (1999) 2943-2949
28. Price R.N., Uhlemann A.C., Brockman A., McGready R., Ashley E., Phaipun L., Patel R., Laing K., Looareesuwan S., White N.J., Nosten F., and Krishna S. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364 9432 (2004) 438-447
29. Reed M.B., Saliba K.J., Caruana S.R., Kirk K., and Cowman A.F. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403 6772 (2000) 906-909
30. Schneider A.G., Premji Z., Felger I., Smith T., Abdulla S., Beck H.P., and Mshinda H. A point mutation in codon 76 of pfcrt of P. falciparum is positively selected for by Chloroquine treatment in Tanzania. Infect. Genet. Evol. 1 3 (2002) 183-189
31. Snounou G., Zhu X., Siripoon N., Jarra W., Thaithong S., Brown K.N., and Viriyakosol S. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans. R. Soc. Trop. Med. Hyg. 93 4 (1999) 369-374
32. Veiga M.I., Ferreira P.E., Bjorkman A., and Gil J.P. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol. Cell Probes 20 2 (2006) 100-104
33. Walliker D., Hunt P., and Babiker H. Fitness of drug-resistant malaria parasites. Acta Trop. 94 3 (2005) 251-259
34. Warhurst D.C. Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. Malar. J. 2 (2003) 31
35. White N.J. Preventing antimalarial drug resistance through combinations. Drug. Resist. Updat. 1 1 (1998) 3-9
36. WHO, 2001. Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation. Geneva, April 4-5, WHO/CDS/RBM/2001.35.